化学
结合
单克隆抗体
抗体-药物偶联物
重组DNA
药品
体内
组合化学
癌细胞
癌症研究
癌症
抗体
细胞毒性
癌症治疗
连接器
铅化合物
药物发现
计算生物学
肿瘤细胞
抗癌药
细胞培养
类有机物
体外
过程(计算)
癌症免疫疗法
细胞
癌症治疗
生物化学
抗原
药理学
纳米技术
生物物理学
生物活性
药物开发
微管
作者
Tianshui Xue,Na Li,Zhizhou Yang,Jinbao Tang,Yanhong Ding,Jinheng Pan,Zhenyu Ju,Ningning Wang,Bowen Yu
标识
DOI:10.1021/acs.jmedchem.6c02191
摘要
Abstract Accurate and effective treatment of solid tumors has long been a core issue in cancer therapy. Antibody-drug conjugates (ADCs) represent a crucial breakthrough in precision oncology. Traditional ADCs rely on monoclonal antibodies generated through animal immunization, followed by screening, sequencing, and recombinant expressiona process that is experimentally complex and costly. In this study, we employed deep learning-based computational design methods to design mini-protein binders targeting the tumor-associated antigen TROP2. The designed TROP2 mini-protein binder exhibited high specificity and thermal stability. The binding affinity was optimized from 40.4 nM to 628 pM through partial diffusion. On this basis, we engineered the mini-protein binder by conjugating it with the microtubule inhibitor VcMMAE, thereby constructing mini-protein drug conjugates (MPDCs) that can specifically target and kill TROP2-positive tumor cells. A comprehensive assessment of the anti-tumor efficacy of these MPDCs was performed using cancer cell lines, organoid models, and mouse xenograft models.
科研通智能强力驱动
Strongly Powered by AbleSci AI